Chemotherapy for Advanced Stage Non-Small Cell Lung Cancer

Amir T. Fathi, Julie R. Brahmer

Research output: Contribution to journalArticlepeer-review


Non-small cell lung cancer (NSCLC) is a common, often fatal malignancy, and is most frequently diagnosed in the advanced stage. Systemic chemotherapy for advanced (Stage IIIB and IV), inoperable NSCLC has evolved over the course of the last few decades. Survival advantage was first noted with platinum chemotherapy, with ultimate development of platinum-containing doublet combinations, which have now become standard of care in the treatment of advanced NSCLC. Over the course of the last few years, multiple nonplatinum combinations have also been demonstrated to be efficacious, and the addition of bevacizumab to existing doublet regimens has improved outcomes in this population of patients. Maintenance regimens for advanced stage NSCLC are currently under extensive investigation. Clinical trials have also recently demonstrated increased efficacy for agents such as docetaxel and pemetrexed in the second line setting for refractory disease.

Original languageEnglish (US)
Pages (from-to)210-216
Number of pages7
JournalSeminars in thoracic and cardiovascular surgery
Issue number3
StatePublished - Sep 2008


  • advanced stage
  • combination chemotherapy
  • non-small cell lung cancer
  • systemic therapy

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Chemotherapy for Advanced Stage Non-Small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this